Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 148-154

  Hernick, Marcy ^a   Borch, Richard F ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; INDOLEQUINONE PHOSPHORAMIDATE; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHORUS 31; PRODRUG; SULFUR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVATION; DRUG MECHANISM; DRUG RESEARCH; ELECTRON; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REDUCTION;

ANTINEOPLASTIC AGENTS; MAGNETIC RESONANCE SPECTROSCOPY; ORGANOPHOSPHORUS COMPOUNDS; OXIDATION-REDUCTION; PRODRUGS; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037413556     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0203229     Document Type: Article

References (40)

1. 1H-indole-4,7-dione] prop-en-ol (EO9) by human DT-Diaphorase. Biochem. Pharmacol. 1996, 52, 1711-1718.
2. Beall, H. D.; Hudnott, A. R.; Winski, S.; Siegel, D.; Swann, E.; Ross, D.; Moody, C. J. Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1. Bioorg. Med. Chem. Lett. 1998, 8, 545-548.
3. Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; O'Sullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: Quinone oxidoreductase, and in vitro cytotoxicity. J. Med. Chem. 1998, 41, 4755-4766.
4. Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.; Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis, M. F.; Stratford, M. R. L.; Wardman, P.; Adams, G. E.; Moody, C. J.; Stratford, I. J. Indolequinone antitumor agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl) methyl derivatives and hypoxia-selective cytotoxicity in vitro. J. Med. Chem. 1998, 41, 2720-2731.
5. Swann, E.; Barraja, P.; Oberlander, A.; Gardipee, W.; Hudnott, A.; Beall, H.; Moody, C. Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. J. Med. Chem. 2001, 44, 3311-3319.
6. Oostveen, E. A.; Speckamp, W. N. Mitomycin analogues.1.Indolequinones as (potential) bisalkylating agents. Tetrahedron 1987, 43, 255-262.
7. Workman, P. Enzyme-directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol. Res. 1994, 6, 461-475.
8. Gutierrez, P. L. The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: A review. Free Radical Biol. Med. 2000, 29, 263-275.
9. Ross, D.; Siegel, D.; Beall, H.; Prakash, A. S.; Mulcahy, R. T.; Gibson, N. W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of Mitomycin C. [Review]. Cancer Metastasis Rev. 1993, 12, 83-101.
10. Smith, M. T.; Eastmond, D. A.; Di Monte, D. The activation and detoxification of quinones by DT-diaphorase. Chim. Script. 1987, 27A, 105-107.
11. Paz, M. M.; Das, A.; Tomasz, M. Mitomycin C linked to DNA minor groove binding agents: Synthesis, reductive activation, DNA binding and cross-linking properties and in vitro antitumor activity. Bioorg. Med. Chem. 1999, 7, 2713-2726.
12. Moody, C. J.; Swann, E. Novel bioreductive anticancer agents based on indolequinones. Farmaco 1997, 52, 271-279.
13. Orlemans, E. O. M.; Verboom, W.; Scheltinga, M. W.; Reinhoudt, D. N.; Lelieveld, P.; Fiebig, H. H.; Winterhalter, B. R.; Double, J. A.; Bibby, M. C. Synthesis, mechanism of action, and biological evaluation of mitosenes. J. Med. Chem. 1989, 32, 1612-1620.
14. Hernick, M.; Flader, C.; Borch, R. F. Design, synthesis and biological evaluation ofindolequinone phosphoramidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 2002, 45, 3540-3548.
15. Colvin, M.; Brundrett, R. B.; Kan, M.-N. N.; Jardine, I.; Fenselau, C. Alkylating properties ofphosphoramide mustard. Cancer Res. 1976, 36, 1121-1126.
16. Cummings, J.; Spanswick, V. J.; Smyth, J. F. Reevaluation of the molecular pharmacology of mitomycin C. Eur. J. Cancer 1995, 31A, 1928-1933.
17. Spanswick, V. J.; Cummings, J.; Smyth, J. F. Enzymology of mitomycin C metabolic activation in tumour tissues. Characterization of a novel mitochondrial reductase. Biochem. Pharmacol. 1996, 51, 1623-1630.
18. Cummings, J.; Spanswick, V. J.; Tomasz, M.; Smyth, J. F. Enzymology of mitomycin C metabolic activation in tumour tissue. Biochem. Pharmacol. 1998, 56, 405-414.
19. Spanswick, V. J.; Cummings, J.; Smyth, J. F. Current issues in the enzymology of mitomycin C metabolic activation. Gen. Pharmacol. 1998, 31, 539-544.
20. Cummings, J.; Spanswick, V. J.; Tomasz, M.; Smyth, J. F. Enzymology of mitomycin C metabolic activation in tumour tissue. Implications for enzyme-directed bioreductive drug development. Biochem. Pharmacol. 1998, 56, 405-414.
21. Gustafson, D. L.; Pritsos, C. A. Enhancement of xanthine dehydrogenase mediated mitomycin C metabolism by dicumarol. Cancer Res. 1992, 52, 6936-6939.
22. Gustafson, D. L.; Pritsos, C. A. Kinetics and mechanism of mitomycin C bioactivation by xanthine dehydrogenase under aerobic and hypoxic conditions. Cancer Res. 1993, 53, 5470-5474.
23. Wilson, W. R.; Tercel, M.; Anderson, R. F.; Denny, W. A. Radiation-activated prodrugs as hypoxia-selective cytotoxins: Model studies with nitroarylmethyl quaternary salts. Anti-Cancer Drug Design 1998, 13, 663-685.
24. Everett, S. A.; Naylor, M. A.; Nolan, J.; Patel, K. B.; Wardman, P. Indolequinone bioreductive drugs: Kinetic factors which influence selectivity for hypoxia. Anti-Cancer Drug Design 1998, 13, 635-653.
25. Jaffar, M.; Everett, S. A.; Naylor, M.; Moore, S. G.; Ulhaq, S.; Patel, K. Prodrugs for targeting hypoxic tissues: Regiospecific elimination of aspirin from reduced indoloquinones. Bioorg. Med. Chem. Lett. 1999, 9, 113-118.
26. Swann, E.; Moody, C. J.; Stratford, M. R. L.; Patel, K. B.; Naylor, M. A.; Vojnovic, B.; Wardman, P.; Everett, S. A. Rates of reductive elimination of substituted nitrophenols from the (indol-3-yl)methyl position of indolequinones. J. Chem. Soc., Perkin Trans. 2 2001, 1340-1345.
27. Everett, S. A.; Naylor, M. A.; Barraja, P.; Swann, E.; Patel, K. B.; Stratford, M. R. L.; Hudnott, A. R.; Vojnovic, B.; Locke, R. J.; Wardman, P.; Moody, C. J. Controlling the rates of reductively activated elimination from the (indol-3-yl)methyl position of indolequinones. J. Chem. Soc., Perkin Trans. 2 2001, 843-860.
28. Jaffar, M.; Everett, S. A.; Naylor, M.; Moore, S. G.; Ulhaq, S.; Patel, K. Prodrugs for targeting hypoxic tissues: Regiospecific elimination of aspirin from reduced indoloquinones. Bioorg. Med. Chem. Lett. 1999, 9, 113-118.
29. Everett, S. A.; Swann, E.; Naylor, M. A.; Stratford, M. R. L.; Patel, K. B.; Tian, N.; Newman, R. G.; Vojnovic, B.; Moody, C. J.; Wardman, P. Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: A key factor in controlling hypoxia-selective drug release. Biochem. Pharmacol. 2002, 63, 1629-1639.
30. Teijeiro, C.; Perez, P.; Marin, D.; Palecek, E. Cyclic voltammetry of mitomycin C and DNA. Bioelectrochem. Bioenerget. 1995, 38, 77-83.
31. Maliepaard, M.; de Mol, N. J.; Janssen, L. H. M.; Hoogvliet, J. C.; van der Neut, W.; Verboom, W.; Reinhoudt, D. N. Reductive activation of potential antitumor mitosene compounds. J. Med. Chem. 1993, 36, 2091-2097.
32. Cotterill, A. S.; Moody, C. J.; Mortimer, R. J.; Norton, C. L.; O'Sullivan, N.; Stephens, M. A.; Stradiotto, N. R.; Swann, E.; Stratford, I. J. Cyclopropamitosenes, novel bioreductive anti-cancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones. J. Med. Chem. 1994, 37, 3834-3843.
33. Shyam, K.; Penketh, P. G.; Shapiro, M.; Belcourt, M. F.; Loomis, R. H.; Rockwell, S.; Sartorelli, A. C. Hypoxia-selective nitrobenzylcarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines. J. Med. Chem. 1999, 42, 941-946.
34. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994, 54, 4313-4320.
35. O'Brien, M. L.; Tew, K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 1996, 32A, 967-978.
36. Schultz, M.; Dutta, S.; Tew, K. D. Inhibitors of glutathione S-transferase as therapeutic agents. Adv. Drug Delivery Rev. 1997, 26, 91-104.
37. Flader, C.; Liu, J.; Borch, R. F. Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase. J. Med. Chem. 2000, 43, 3157-3167.
38. Shulman-Roskes, E. M.; Noe, D. A.; Gamcsik, M. P.; Marlow, A. L.; Hilton, J.; Hausheer, F. H.; Calvin, O. M.; Ludeman, S. M. The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions. J. Med. Chem. 1998, 41, 515-529.
39. Boal, J. H.; Williamson, M.; Boyd, V. L.; Ludeman, S. M.; Egan, W. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: Comparisons with phosphoramide mustard. J. Med. Chem. 1989, 32, 1768-1773.
40. Buxton, G. V.; Stuart, C. R. Reevaluation of the thiocyanate dosimeter for pulse radiolysis. J. Chem. Soc., Faraday Trans. 1995, 91, 279-281.